Top Story

Data show encouraging advances in treatment of AML

December 17, 2014

SAN FRANCISCO – According to preliminary data presented at the ASH Annual Meeting and Exposition, FLT3 inhibitors have been shown to have a dramatic, positive effect on patients with acute myeloid leukemia and their chance of survival.

“FLT3 inhibitors can inhibit the activity of FLT3 dramatically after transplantation,” Edward A. Copelan, MD, FACP, chair of the department of hematologic oncology and blood disorders at Levine Cancer Institute told HemOnc Today. “There is a hint that survival is improved by this and the survival curves looked excellent. So in this respect, identifying patients in small subsets of AML, and this is probably 25% of patients, and treating them in a unique way seems to improve survival and offer substantial progress for the future.”

In the Journals

More studies urged in managing posttreatment fatigue in thyroid cancer

December 17, 2014
A paucity of reliable trials exists to guide evidence-based management of posttreatment fatigue in thyroid cancer survivors, according to a systematic review published…
Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease In the Journals

Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease

December 17, 2014
An analysis of genomic rearrangements detected by a diagnostic lineage test helped determine whether multiple non–small cell lung cancer tumors were independent…
FDA approvals

FDA expands approval of Cyramza to include aggressive NSCLC

December 17, 2014
The FDA expanded the approved use of ramucirumab to include use in combination with docetaxel for second-line treatment of patients with metastatic non–small cell…
Jean M. Weigert, MD, FACR Meeting News Coverage

Ultrasound improved cancer detection in women with dense breasts

December 17, 2014
SAN ANTONIO — Women with dense breasts who underwent ultrasound had cancers detected that were missed during screening mammography, according to results of a…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

December 12, 2014
SAN ANTONIO — Erin W. Hofstatter, MD, director of the Breast Cancer Genetics and Prevention Program at Yale…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan morganatic-roan